世界の製薬業界の最新ニュースと解説

【デジタルヘルスケア】ビッグデータの活用で製薬会社は企業利益を生むことができるか?

今や一時的なブームではなくなったビッグデータには、製薬会社の商業的成果を根本から変える可能性が秘められています。このレポートは、製薬会社のデータ革命最前線に身を置く11人の専門家へのインタビューを行い、ビッグデータから商業的可能性を最大限に引き出す方法などを聞いています。

発行会社: FirstWord
コンセプト: Digital Health
ページ数: お問合せ下さい。
発行日: 2016年9月
価格(シングル): $695
価格(国内): $2,850
価格(グローバル): $5,650
フォーマット: PDF
レポートコード:
596200511
英文タイトル: Powering Commercial Effectiveness Through Big Data and Analytics
  • Brad Ashby: Director of Commercial Operations, Kaléo Pharmaceuticals
  • Blanca Rosales Baez: Executive Advisor – Business Development Big Data Analytics for Precision Medicine,
  • Molecular Health GmbH
  • Peter Barschdorff: Vice President of Business Insights at Bayer: Market Research, Commercial Analytics and Commercial Reporting (Quotes attributed to him are his personal opinion and do not in any way represent Bayer Pharmaceuticals’ opinions or business practices)
  • Hassan Chaudhury: Chief Commercial Officer, Health iQ
  • David Latshaw II: Scientist at The Janssen Pharmaceutical Companies of Johnson & Johnson
  • Manish Mathur: Senior Director, Data Strategy and Management for Commercial Excellence, at Janssen Pharmaceuticals, of Johnson & Johnson (Views made in this report are his personal opinion and are not intended to represent the views of Johnson & Johnson)
  • Irina Osovskaya: Global Director of Mobile and Customer Experience Strategy at AstraZeneca
  • Anders Quitzau: Innovation Executive, Watson Advocate
  • Ian Talmage: Senior Vice President, Global Marketing at Bayer Pharmaceuticals
  • John Michael Veik: Large Enterprise Sales, IBM
  • Anonymous: The personal (non-Agency) opinion of a recent FDA employee